-metinib
Drugs that block MEK, a kinase in the MAPK growth pathway.
- Drugs ending in -metinib: 15
- Approved somewhere: 4
- With a US drug page: 4
Approved and clinical-stage drugs in ChEMBL whose names ending in -metinib, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Binimetinib | Approved | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Cobimetinib | Approved | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Trametinib | Approved | MAP2K2, MAP2K1, MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 2 inhibitor |
| Mirdametinib | Phase 2 | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Selumetinib | Approved | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Avutometinib | Phase 3 | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Tunlametinib | Phase 3 | — | — |
| Gamcemetinib | Phase 2 | — | — |
| Luvometinib | Phase 2 | — | — |
| Nedometinib | Phase 2 | — | — |
| Ralimetinib | Phase 2 | MAPK14 | MAP kinase p38 alpha inhibitor |
| Refametinib | Phase 2 | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Zapnometinib | Phase 2 | — | — |
| Zunsemetinib | Phase 2 | — | — |
| Pexmetinib | Phase 1 | MAPK14, TEK | MAP kinase p38 alpha inhibitor |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO